Expressed cell-penetrating peptides can induce a bystander effect, but passage through the secretory pathway reduces protein transduction activity

Molecular Therapy

Volumn 19, Issue 5, 2011, Pages 903-912

  Shen, Ying ^a   Yu, William ^a   Hay, John G ^a,b   Sauthoff, Harald ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CELL PENETRATING PEPTIDE; FURIN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; RED FLUORESCENT PROTEIN; SECRETORY PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; BYSTANDER EFFECT; CHERRY; CONTROLLED STUDY; CYTOLYSIS; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN SECRETION; SECRETORY PATHWAY; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79955623951     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.283     Document Type: Article

References (34)

1. Frankel, AD and Pabo, CO (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193. (Pubitemid 19020071)
2. Vivès, E, Brodin, P and Lebleu, B (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010-16017. (Pubitemid 27265584)
3. Heitz, F, Morris, MC and Divita, G (2009). Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157: 195-206.
4. Ensoli, B, Barillari, G, Salahuddin, SZ, Gallo, RC and Wong-Staal, F (1990). Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345: 84-86.
5. Chang, HC, Samaniego, F, Nair, BC, Buonaguro, L and Ensoli, B (1997). HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11: 1421-1431. (Pubitemid 27421173)
6. Ensoli, B, Buonaguro, L, Barillari, G, Fiorelli, V, Gendelman, R, Morgan, RA et al. (1993). Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67: 277-287. (Pubitemid 23002988)
7. Marchiò, S, Alfano, M, Primo, L, Gramaglia, D, Butini, L, Gennero, L et al. (2005). Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood 105: 2802-2811. (Pubitemid 40446273)
8. Rayne, F, Debaisieux, S, Bonhoure, A and Beaumelle, B (2010). HIV-1 Tat is unconventionally secreted through the plasma membrane. Cell Biol Int 34: 409-413.
9. Rayne, F, Debaisieux, S, Yezid, H, Lin, YL, Mettling, C, Konate, K et al. (2010). Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J 29: 1348-1362.
10. Xiao, H, Neuveut, C, Tiffany, HL, Benkirane, M, Rich, EA, Murphy, PM et al. (2000). Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 97: 11466-11471.
11. Tyagi, M, Rusnati, M, Presta, M and Giacca, M (2001). Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276: 3254-3261.
12. Cashman, SM, Morris, DJ and Kumar-Singh, R (2003). Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and in vivo. Mol Ther 8: 130-142. (Pubitemid 36939304)
13. Tasciotti, E and Giacca, M (2005). Fusion of the human immunodeficiency virus type 1 tat protein transduction domain to thymidine kinase increases bystander effect and induces enhanced tumor killing in vivo. Hum Gene Ther 16: 1389-1403. (Pubitemid 41829014)
14. Cascante, A, Huch, M, Rodríguez, LG, González, JR, Costantini, L and Fillat, C (2005). Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression in vivo. Hum Gene Ther 16: 1377-1388. (Pubitemid 41829013)
15. Xia, H, Mao, Q and Davidson, BL (2001). The HIV Tat protein transduction domain improves the biodistribution of α-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 19: 640-644. (Pubitemid 32625434)
16. Flinterman, M, Farzaneh, F, Habib, N, Malik, F, Gäken, J and Tavassoli, M (2009). Delivery of therapeutic proteins as secretable TAT fusion products. Mol Ther 17: 334-342.
17. Koutsokeras, A and Kabouridis, PS (2009). Secretion and uptake of TAT-fusion proteins produced by engineered mammalian cells. Biochim Biophys Acta 1790: 147-153.
18. Shaw, PA, Catchpole, IR, Goddard, CA and Colledge, WH (2008). Comparison of protein transduction domains in mediating cell delivery of a secreted CRE protein. Biochemistry 47: 1157-1166. (Pubitemid 351161872)
19. Barka, T, Gresik, ES and Henderson, SC (2004). Production of cell lines secreting TAT fusion proteins. J Histochem Cytochem 52: 469-477. (Pubitemid 38420381)
20. White, MK, Amini, S, Khalili, K, Kogan, M, Donaldson, K and Darbinian, N (2008). Development of a bidirectional caspase-3 expression system for the induction of apoptosis. Cancer Biol Ther 7: 945-954.
21. Barash, S, Wang, W and Shi, Y (2002). Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression. Biochem Biophys Res Commun 294: 835-842. (Pubitemid 34687192)
22. Tikhonov, I, Ruckwardt, TJ, Berg, S, Hatfield, GS and David Pauza, C (2004). Furin cleavage of the HIV-1 Tat protein. FEBS Lett 565: 89-92. (Pubitemid 38595325)
23. Ho, A, Schwarze, SR, Mermelstein, SJ, Waksman, G and Dowdy, SF (2001). Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 61: 474-477. (Pubitemid 32128600)
24. Klausner, RD, Donaldson, JG and Lippincott-Schwartz, J (1992). Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol 116: 1071-1080.
25. Ruben, S, Perkins, A, Purcell, R, Joung, K, Sia, R, Burghoff, R et al. (1989). Structural and functional characterization of human immunodeficiency virus tat protein. J Virol 63: 1-8. (Pubitemid 19028076)
26. Yang, Y, Ma, J, Song, Z and Wu, M (2002). HIV-1 TAT-mediated protein transduction and subcellular localization using novel expression vectors. FEBS Lett 532: 36-44. (Pubitemid 35375863)
27. Yoon, JS, Jung, YT, Hong, SK, Kim, SH, Shin, MC, Lee, DG et al. (2004). Characteristics of HIV-Tat protein transduction domain. J Microbiol 42: 328-335.
28. Leifert, JA, Harkins, S and Whitton, JL (2002). Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther 9: 1422-1428. (Pubitemid 35345570)
29. Leifert, JA and Whitton, JL (2003). "Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanisms. Mol Ther 8: 13-20. (Pubitemid 36939292)
30. Li, Y, Rosal, RV, Brandt-Rauf, PW and Fine, RL (2002). Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide. Biochem Biophys Res Commun 298: 439-449. (Pubitemid 35333726)
31. Wadia, JS, Stan, RV and Dowdy, SF (2004). Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10: 310-315. (Pubitemid 38667624)
32. Duchardt, F, Fotin-Mleczek, M, Schwarz, H, Fischer, R and Brock, R (2007). A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8: 848-866. (Pubitemid 46971632)
33. Richard, JP, Melikov, K, Vives, E, Ramos, C, Verbeure, B, Gait, MJ et al. (2003). Cellpenetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278: 585-590. (Pubitemid 36043612)
34. Graham, FL and Prevec, L (1995). Methods for construction of adenovirus vectors. Mol Biotechnol 3: 207-220.